Logo image of SDGR

SCHRODINGER INC (SDGR) Stock Overview

USA - NASDAQ:SDGR - US80810D1037 - Common Stock

22.52 USD
+0.56 (+2.55%)
Last: 10/24/2025, 8:00:02 PM
22.7 USD
+0.18 (+0.8%)
After Hours: 10/24/2025, 8:00:02 PM

SDGR Key Statistics, Chart & Performance

Key Statistics
Market Cap1.66B
Revenue(TTM)237.92M
Net Income(TTM)-181333000
Shares73.61M
Float62.74M
52 Week High28.47
52 Week Low16.6
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.48
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/amc
IPO2020-02-06
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Technology
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Technology


SDGR short term performance overview.The bars show the price performance of SDGR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

SDGR long term performance overview.The bars show the price performance of SDGR in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 20

The current stock price of SDGR is 22.52 USD. In the past month the price increased by 16.68%. In the past year, price increased by 27.38%.

SCHRODINGER INC / SDGR Daily stock chart

SDGR Latest News, Press Relases and Analysis

SDGR Competitors/Peers

The largest stocks on the US markets in the "Health Care Technology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
VEEV VEEVA SYSTEMS INC-CLASS A 39.33 48.03B
DOCS DOXIMITY INC-CLASS A 44.86 12.52B
WAY WAYSTAR HOLDING CORP 35.11 7.44B
HTFL HEARTFLOW INC N/A 3.16B
CERT CERTARA INC 25.84 2.03B
TDOC TELADOC HEALTH INC N/A 1.67B
PHR PHREESIA INC N/A 1.41B
GDRX GOODRX HOLDINGS INC-CLASS A 11.29 1.37B
CTEV CLARITEV CORP N/A 1.15B
LFMDP LIFEMD INC - LFMD 8 7/8 PERP N/A 1.07B
EVH EVOLENT HEALTH INC - A N/A 917.75M
CCLDO CARECLOUD INC - CCLD 8 3/4 PERP N/A 909.88M

About SDGR

Company Profile

SDGR logo image Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 891 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

Company Info

SCHRODINGER INC

1540 Broadway, 24th Floor

New York City NEW YORK 10036 US

CEO: Ramy Farid

Employees: 891

SDGR Company Website

SDGR Investor Relations

Phone: 15032991150

SCHRODINGER INC / SDGR FAQ

What does SCHRODINGER INC do?

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 891 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.


What is the stock price of SCHRODINGER INC today?

The current stock price of SDGR is 22.52 USD. The price increased by 2.55% in the last trading session.


Does SDGR stock pay dividends?

SDGR does not pay a dividend.


How is the ChartMill rating for SCHRODINGER INC?

SDGR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


How is the valuation of SCHRODINGER INC (SDGR) based on its PE ratio?

SCHRODINGER INC (SDGR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.48).


Can you provide the growth outlook for SCHRODINGER INC?

The Revenue of SCHRODINGER INC (SDGR) is expected to grow by 23.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the market capitalization of SDGR stock?

SCHRODINGER INC (SDGR) has a market capitalization of 1.66B USD. This makes SDGR a Small Cap stock.


SDGR Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to SDGR. When comparing the yearly performance of all stocks, SDGR is one of the better performing stocks in the market, outperforming 74.6% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SDGR Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to SDGR. No worries on liquidiy or solvency for SDGR as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SDGR Financial Highlights

Over the last trailing twelve months SDGR reported a non-GAAP Earnings per Share(EPS) of -2.48. The EPS increased by 10.47% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -26.35%
ROE -52.89%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%20.27%
Sales Q2Q%15.69%
EPS 1Y (TTM)10.47%
Revenue 1Y (TTM)18.59%

SDGR Forecast & Estimates

16 analysts have analysed SDGR and the average price target is 28.67 USD. This implies a price increase of 27.32% is expected in the next year compared to the current price of 22.52.

For the next year, analysts expect an EPS growth of 7.29% and a revenue growth 23.48% for SDGR


Analysts
Analysts80
Price Target28.67 (27.31%)
EPS Next Y7.29%
Revenue Next Year23.48%

SDGR Ownership

Ownership
Inst Owners108.15%
Ins Owners2.65%
Short Float %15.47%
Short Ratio8.69